Eurus Therapeutics Inc.
2 known investors
Find your way into Eurus Therapeutics Inc.
Sign up to see every warm intro you have to Eurus Therapeutics Inc.
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Eurus Therapeutics Inc. team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Eurus Therapeutics develops genetic medicines using its genome integration technology, which inserts large DNA cargos at specific sites without nuclease-mediated DNA cleavage for durable therapeutic expression. Its programs target gene replacement for monogenic diseases, in vivo immune cell engineering (CAR-T), and in-body therapeutic protein production.
Founders & leadership
TN
Takato NoumiFounder & CEO
NI
Naoki InoueCOO
RA
Ryo ArashidaVice President, IP Strategy
Investors · 2
Frequently asked questions
- What does Eurus Therapeutics Inc. do?
- Eurus Therapeutics develops genetic medicines using its genome integration technology, which inserts large DNA cargos at specific sites without nuclease-mediated DNA cleavage for durable therapeutic expression. Its programs target gene replacement for monogenic diseases, in vivo immune cell engineering (CAR-T), and in-body therapeutic protein production.
- Who are Eurus Therapeutics Inc.'s investors?
- Eurus Therapeutics Inc.'s investors include Kyoto University Innovation Capital, Axil Capital.
